STEVANATO GROUP SPA (STVN) Stock Fundamental Analysis
NYSE:STVN - IT0005452658 - Common Stock
22.62 USD
-0.23 (-1.01%)
Overall STVN gets a fundamental rating of 5 out of 10. We evaluated STVN against 54 industry peers in the Life Sciences Tools & Services industry. While STVN has a great profitability rating, there are some minor concerns on its financial health. STVN is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year STVN was profitable.
In the past year STVN had a positive cash flow from operations.
STVN had positive earnings in each of the past 5 years.
Each year in the past 5 years STVN had a positive operating cash flow.
1.2 Ratios
The Return On Assets of STVN (5.72%) is better than 81.48% of its industry peers.
The Return On Equity of STVN (9.63%) is better than 79.63% of its industry peers.
With a decent Return On Invested Capital value of 7.90%, STVN is doing good in the industry, outperforming 79.63% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for STVN is significantly below the industry average of 15.98%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.72% | ||
| ROE | 9.63% | ||
| ROIC | 7.9% |
ROA(3y)6.9%
ROA(5y)7.65%
ROE(3y)11.86%
ROE(5y)15.36%
ROIC(3y)9.71%
ROIC(5y)10.46%
1.3 Margins
STVN has a Profit Margin of 11.75%. This is in the better half of the industry: STVN outperforms 79.63% of its industry peers.
STVN's Profit Margin has improved in the last couple of years.
STVN's Operating Margin of 17.17% is fine compared to the rest of the industry. STVN outperforms 79.63% of its industry peers.
In the last couple of years the Operating Margin of STVN has grown nicely.
The Gross Margin of STVN (28.83%) is worse than 74.07% of its industry peers.
STVN's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 17.17% | ||
| PM (TTM) | 11.75% | ||
| GM | 28.83% |
OM growth 3Y-5.27%
OM growth 5Y7.16%
PM growth 3Y-12.48%
PM growth 5Y7.86%
GM growth 3Y-3.05%
GM growth 5Y2.24%
2. Health
2.1 Basic Checks
STVN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
STVN has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, STVN has less shares outstanding
STVN has a better debt/assets ratio than last year.
2.2 Solvency
STVN has an Altman-Z score of 5.15. This indicates that STVN is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of STVN (5.15) is better than 85.19% of its industry peers.
STVN has a Debt/Equity ratio of 0.24. This is a healthy value indicating a solid balance between debt and equity.
STVN has a Debt to Equity ratio (0.24) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.24 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 5.15 |
ROIC/WACC0.95
WACC8.35%
2.3 Liquidity
A Current Ratio of 1.79 indicates that STVN should not have too much problems paying its short term obligations.
STVN has a worse Current ratio (1.79) than 61.11% of its industry peers.
STVN has a Quick Ratio of 1.22. This is a normal value and indicates that STVN is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.22, STVN is not doing good in the industry: 75.93% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.79 | ||
| Quick Ratio | 1.22 |
3. Growth
3.1 Past
STVN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.00%.
The Earnings Per Share has been growing by 27.29% on average over the past years. This is a very strong growth
STVN shows a small growth in Revenue. In the last year, the Revenue has grown by 5.28%.
STVN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.53% yearly.
EPS 1Y (TTM)4%
EPS 3Y-6.42%
EPS 5Y27.29%
EPS Q2Q%22.22%
Revenue 1Y (TTM)5.28%
Revenue growth 3Y9.37%
Revenue growth 5Y15.53%
Sales Q2Q%7.86%
3.2 Future
Based on estimates for the next years, STVN will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.61% on average per year.
STVN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.95% yearly.
EPS Next Y12.43%
EPS Next 2Y17.31%
EPS Next 3Y19.17%
EPS Next 5Y17.61%
Revenue Next Year7.25%
Revenue Next 2Y8.78%
Revenue Next 3Y9.35%
Revenue Next 5Y7.95%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 37.08, STVN can be considered very expensive at the moment.
The rest of the industry has a similar Price/Earnings ratio as STVN.
When comparing the Price/Earnings ratio of STVN to the average of the S&P500 Index (26.76), we can say STVN is valued slightly more expensively.
A Price/Forward Earnings ratio of 29.42 indicates a quite expensive valuation of STVN.
Based on the Price/Forward Earnings ratio, STVN is valued a bit cheaper than 68.52% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of STVN to the average of the S&P500 Index (34.91), we can say STVN is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.08 | ||
| Fwd PE | 29.42 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, STVN is valued a bit cheaper than the industry average as 72.22% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 20.54 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of STVN may justify a higher PE ratio.
A more expensive valuation may be justified as STVN's earnings are expected to grow with 19.17% in the coming years.
PEG (NY)2.98
PEG (5Y)1.36
EPS Next 2Y17.31%
EPS Next 3Y19.17%
5. Dividend
5.1 Amount
With a yearly dividend of 0.28%, STVN is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 0.54, STVN pays a better dividend. On top of this STVN pays more dividend than 83.33% of the companies listed in the same industry.
With a Dividend Yield of 0.28, STVN pays less dividend than the S&P500 average, which is at 2.36.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.28% |
5.2 History
STVN has been paying a dividend for less than 5 years, so it still needs to build a track record.
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
STVN pays out 10.74% of its income as dividend. This is a sustainable payout ratio.
DP10.74%
EPS Next 2Y17.31%
EPS Next 3Y19.17%
NYSE:STVN (8/22/2025, 4:04:02 PM)
22.62
-0.23 (-1.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners112.76%
Inst Owner Change-4.96%
Ins Owners1.61%
Ins Owner ChangeN/A
Market Cap6.17B
Analysts83.53
Price Target28.86 (27.59%)
Short Float %4.15%
Short Ratio5.79
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.28% |
Yearly Dividend0.06
Dividend Growth(5Y)N/A
DP10.74%
Div Incr Years1
Div Non Decr Years1
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.49%
Min EPS beat(2)2.71%
Max EPS beat(2)10.28%
EPS beat(4)3
Avg EPS beat(4)1.61%
Min EPS beat(4)-7.68%
Max EPS beat(4)10.28%
EPS beat(8)3
Avg EPS beat(8)-5.73%
EPS beat(12)6
Avg EPS beat(12)-2.97%
EPS beat(16)10
Avg EPS beat(16)0.11%
Revenue beat(2)2
Avg Revenue beat(2)2.02%
Min Revenue beat(2)1.72%
Max Revenue beat(2)2.33%
Revenue beat(4)3
Avg Revenue beat(4)0.99%
Min Revenue beat(4)-0.71%
Max Revenue beat(4)2.33%
Revenue beat(8)3
Avg Revenue beat(8)-0.93%
Revenue beat(12)4
Avg Revenue beat(12)-0.39%
Revenue beat(16)7
Avg Revenue beat(16)-0.02%
PT rev (1m)3.3%
PT rev (3m)5.03%
EPS NQ rev (1m)-6.18%
EPS NQ rev (3m)-11.68%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.17%
Revenue NQ rev (1m)-1.82%
Revenue NQ rev (3m)-3.13%
Revenue NY rev (1m)-0.08%
Revenue NY rev (3m)0.17%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.08 | ||
| Fwd PE | 29.42 | ||
| P/S | 4.63 | ||
| P/FCF | N/A | ||
| P/OCF | 25.68 | ||
| P/B | 3.79 | ||
| P/tB | 4.04 | ||
| EV/EBITDA | 20.54 |
EPS(TTM)0.61
EY2.7%
EPS(NY)0.77
Fwd EY3.4%
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)0.88
OCFY3.89%
SpS4.88
BVpS5.96
TBVpS5.61
PEG (NY)2.98
PEG (5Y)1.36
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 5.72% | ||
| ROE | 9.63% | ||
| ROCE | 10.51% | ||
| ROIC | 7.9% | ||
| ROICexc | 8.32% | ||
| ROICexgc | 8.73% | ||
| OM | 17.17% | ||
| PM (TTM) | 11.75% | ||
| GM | 28.83% | ||
| FCFM | N/A |
ROA(3y)6.9%
ROA(5y)7.65%
ROE(3y)11.86%
ROE(5y)15.36%
ROIC(3y)9.71%
ROIC(5y)10.46%
ROICexc(3y)11.09%
ROICexc(5y)13.59%
ROICexgc(3y)11.88%
ROICexgc(5y)15.21%
ROCE(3y)13.31%
ROCE(5y)14.16%
ROICexcg growth 3Y-28.59%
ROICexcg growth 5Y-6.94%
ROICexc growth 3Y-26.56%
ROICexc growth 5Y-4.42%
OM growth 3Y-5.27%
OM growth 5Y7.16%
PM growth 3Y-12.48%
PM growth 5Y7.86%
GM growth 3Y-3.05%
GM growth 5Y2.24%
F-Score5
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.24 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 1.24 | ||
| Cap/Depr | 338.93% | ||
| Cap/Sales | 23.63% | ||
| Interest Coverage | 22.83 | ||
| Cash Conversion | 74.71% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.79 | ||
| Quick Ratio | 1.22 | ||
| Altman-Z | 5.15 |
F-Score5
WACC8.35%
ROIC/WACC0.95
Cap/Depr(3y)442.35%
Cap/Depr(5y)341.04%
Cap/Sales(3y)31.28%
Cap/Sales(5y)24.35%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4%
EPS 3Y-6.42%
EPS 5Y27.29%
EPS Q2Q%22.22%
EPS Next Y12.43%
EPS Next 2Y17.31%
EPS Next 3Y19.17%
EPS Next 5Y17.61%
Revenue 1Y (TTM)5.28%
Revenue growth 3Y9.37%
Revenue growth 5Y15.53%
Sales Q2Q%7.86%
Revenue Next Year7.25%
Revenue Next 2Y8.78%
Revenue Next 3Y9.35%
Revenue Next 5Y7.95%
EBIT growth 1Y6.16%
EBIT growth 3Y3.61%
EBIT growth 5Y23.8%
EBIT Next Year70.56%
EBIT Next 3Y33.35%
EBIT Next 5Y23.77%
FCF growth 1Y70.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.91%
OCF growth 3Y5.33%
OCF growth 5Y29.6%